利妥昔单抗成功诱导治疗儿童孤立性寡免疫性肺毛细血管炎所致弥漫性肺泡出血
本文报告一例青少年女性孤立性寡免疫性毛细血管炎(IPPC)表现为弥漫性肺泡出血,采用静脉利妥昔单抗联合甲泼尼龙冲击治疗成功诱导缓解。IPPC传统上按ANCA相关性血管炎用环磷酰胺和糖皮质激素治疗,但儿科管理证据有限,本病例提示该联合方案可能为儿科IPPC提供可选择的疾病控制手段。
要点
- IPPC是活检见肺小血管毛细血管炎但无系统性疾病的罕见诊断。
- 传统治疗参照ANCA相关性血管炎,使用环磷酰胺和糖皮质激素。
- 青少年IPPC患者经静脉利妥昔单抗联合甲泼尼龙冲击成功诱导缓解。
核心结论
- 静脉利妥昔单抗联合甲泼尼龙冲击可能为儿科IPPC患者提供可行的疾病控制选择。
研究设计与样本
- 本文为个案报告,对象为一名表现为弥漫性肺泡出血的青少年女性IPPC患者。
主要发现
- 该青少年女性IPPC患者经静脉利妥昔单抗联合甲泼尼龙冲击治疗成功诱导缓解。
临床怎么用
- 对儿科IPPC表现为弥漫性肺泡出血者,可考虑静脉利妥昔单抗联合甲泼尼龙冲击作为诱导缓解方案。
局限性
- 文献中描述IPPC管理选择的病例很少,尤其儿科患者,本报告仅为单例经验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diffuse alveolar hemorrhage often presents as dyspnea, cough, or hemoptysis, and it is mediated by both immune and nonimmune processes. Isolated pauci-immune capillaritis (IPPC) is a rare diagnosis in which capillaritis, small-vessel vasculitis of the lung, is found on biopsy in the absence of an underlying systemic disorder. Traditionally, IPPC has been treated similarly to anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis with cyclophosphamide and glucocorticoids. However, few cases describing management options are available in the literature, especially among pediatric patients. Our report of successful induction of remission in an adolescent girl suggests that the combination of IV rituximab and pulse methylprednisolone may be a viable option for disease control in pediatric patients with IPPC.
引用
- Lewinter KE, Cidon M, Warren M, et al. Successful Induction Treatment With Rituximab of Isolated Pauci-Immune Pulmonary Capillaritis Presenting as Diffuse Alveolar Hemorrhage in a Pediatric Patient. Chest. 2020. PMID: 33160541. doi:10.1016/j.chest.2020.06.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。